Latest News

OLN324 vs Vabysmo: How J&J’s $2.2bn Eye Drug Compares

OLN324 vs Vabysmo: How J&J’s $2.2bn Eye Drug Compares

How does OLN324 compare with Vabysmo? In the only head-to-head data found, it dried the retina faster in diabetic macular oedema. However, differences in durability and vision were small. That evidence comes from a 164-patient Phase 1b trial, and no Phase 3 comparison...

read more

Latest News

Hygiene Poverty and the Overlooked Toileting Needs of Women

Hygiene Poverty and the Overlooked Toileting Needs of Women

If you had to choose between food and toilet paper, what would you choose? A UK report from In Kind Direct and The Hygiene Bank found that 47% of people experiencing hygiene poverty had gone without toilet roll, making it the most common product people went without....

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Who Confirms the Alert Before Dawn?

Who Confirms the Alert Before Dawn?

I practice emergency medicine. Overnight care is where timing funds or fails any sepsis early warning tool. A recommendation that sits unconfirmed for hours is not decision support. It is wallpaper. Confirmation is the intervention Accuracy slides still dominate...

read more
The Model Said No. Who Gets to Overrule It?

The Model Said No. Who Gets to Overrule It?

In rare tumors, oncologists know the usual story. PD-L1 is a weak compass. Tumor mutational burden is often unavailable. The evidence base was never built. So when MD Anderson investigators revisited biopsies from 84 patients in a phase 2 basket trial of pembrolizumab...

read more
Weekly News Roundup | 05 October 2026

Weekly News Roundup | 05 October 2026

Life science news 5 October 2026: four US approvals, three deals and two UK regulatory items. The FDA approved Emcitate, which it calls the first treatment for MCT8 deficiency. The FDA approved a heart valve that can be expanded as a child grows. AstraZeneca agreed to...

read more
Why Periodontitis Matters Beyond Dentistry

Why Periodontitis Matters Beyond Dentistry

In brief: Periodontitis, the advanced form of gum disease, is consistently linked with cardiovascular disease, type 2 diabetes and adverse pregnancy outcomes. Only the diabetes link is supported by treatment trials, in which periodontal therapy lowers HbA1c by about...

read more
Low FODMAP Diet and Disordered Eating in IBS

Low FODMAP Diet and Disordered Eating in IBS

A new study published in September has reinforced how, for people with IBS who have been taught the low FODMAP diet, uncontrolled digestive symptoms and psychological distress can be linked to disordered eating behaviours. It can help us think about how patients are...

read more
Clinical Trials Roundup | 2 October 2026

Clinical Trials Roundup | 2 October 2026

The clinical trial results 2 October 2026 span hepatitis delta, wet macular degeneration, Niemann-Pick disease, COVID-19 and skin cancer. Mirum Pharmaceuticals’ brelovitug met its primary endpoint in chronic hepatitis delta. Kodiak Sciences’ Zenkuda and tabirafusp-ted...

read more
Beyond the Scale: Meaningful Follow-Up in GLP-1 Care

Beyond the Scale: Meaningful Follow-Up in GLP-1 Care

A GLP-1 follow-up appointment can produce a clear number without answering the most important question: how is this person doing? Weight remains relevant in obesity care, but a useful review also creates space for symptoms, everyday function and the practical work of...

read more
How AI Is Redefining the Modern Healthcare Consultation

How AI Is Redefining the Modern Healthcare Consultation

Healthcare in the United States is facing a structural inflection point. Physician burnout remains high. Administrative burdens consume hours that should be spent with patients. Chronic disease rates continue to rise. At the same time, health systems are under...

read more
The Writing Got Cheap. The Checking Did Not

The Writing Got Cheap. The Checking Did Not

Last month I published a cost analysis with wrong numbers in it. Not rounded wrong. I had taken the wrong price list and the wrong tariff for cache writes, and when I recomputed, the headline figure moved. I issued a corrected version and stopped citing the first one....

read more
Who Confirms the Alert Before Dawn?

Who Confirms the Alert Before Dawn?

I practice emergency medicine. Overnight care is where timing funds or fails any sepsis early warning tool. A recommendation that sits unconfirmed for hours is not decision support. It is wallpaper. Confirmation is the intervention Accuracy slides still dominate...

read more
The Model Said No. Who Gets to Overrule It?

The Model Said No. Who Gets to Overrule It?

In rare tumors, oncologists know the usual story. PD-L1 is a weak compass. Tumor mutational burden is often unavailable. The evidence base was never built. So when MD Anderson investigators revisited biopsies from 84 patients in a phase 2 basket trial of pembrolizumab...

read more
Weekly News Roundup | 05 October 2026

Weekly News Roundup | 05 October 2026

Life science news 5 October 2026: four US approvals, three deals and two UK regulatory items. The FDA approved Emcitate, which it calls the first treatment for MCT8 deficiency. The FDA approved a heart valve that can be expanded as a child grows. AstraZeneca agreed to...

read more
Why Periodontitis Matters Beyond Dentistry

Why Periodontitis Matters Beyond Dentistry

In brief: Periodontitis, the advanced form of gum disease, is consistently linked with cardiovascular disease, type 2 diabetes and adverse pregnancy outcomes. Only the diabetes link is supported by treatment trials, in which periodontal therapy lowers HbA1c by about...

read more
Low FODMAP Diet and Disordered Eating in IBS

Low FODMAP Diet and Disordered Eating in IBS

A new study published in September has reinforced how, for people with IBS who have been taught the low FODMAP diet, uncontrolled digestive symptoms and psychological distress can be linked to disordered eating behaviours. It can help us think about how patients are...

read more
Clinical Trials Roundup | 2 October 2026

Clinical Trials Roundup | 2 October 2026

The clinical trial results 2 October 2026 span hepatitis delta, wet macular degeneration, Niemann-Pick disease, COVID-19 and skin cancer. Mirum Pharmaceuticals’ brelovitug met its primary endpoint in chronic hepatitis delta. Kodiak Sciences’ Zenkuda and tabirafusp-ted...

read more
Beyond the Scale: Meaningful Follow-Up in GLP-1 Care

Beyond the Scale: Meaningful Follow-Up in GLP-1 Care

A GLP-1 follow-up appointment can produce a clear number without answering the most important question: how is this person doing? Weight remains relevant in obesity care, but a useful review also creates space for symptoms, everyday function and the practical work of...

read more
How AI Is Redefining the Modern Healthcare Consultation

How AI Is Redefining the Modern Healthcare Consultation

Healthcare in the United States is facing a structural inflection point. Physician burnout remains high. Administrative burdens consume hours that should be spent with patients. Chronic disease rates continue to rise. At the same time, health systems are under...

read more
The Writing Got Cheap. The Checking Did Not

The Writing Got Cheap. The Checking Did Not

Last month I published a cost analysis with wrong numbers in it. Not rounded wrong. I had taken the wrong price list and the wrong tariff for cache writes, and when I recomputed, the headline figure moved. I issued a corrected version and stopped citing the first one....

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

The Financial Infrastructure Behind Healthcare Innovation

The Financial Infrastructure Behind Healthcare Innovation

Healthcare is changing faster than I have ever seen it change, and the revenue cycle has to keep pace. We are talking about AI, new treatments, new technology, new specialties and entirely new ways of delivering care. All of that is exciting, and much of it has the...

read more
When the Model Is Confident and the Patient Is Not

When the Model Is Confident and the Patient Is Not

It is 2:07 a.m. in the emergency department. The waiting room is thin. The hallway is not. A middle-aged man looks pale. His vitals sit in the green band. A clinical decision support tile on the chart says low risk with a high confidence score. His wife keeps saying...

read more
China Out-Licensing Deals 2026: The Billion-Dollar Tracker

China Out-Licensing Deals 2026: The Billion-Dollar Tracker

In the first half of 2026, China’s innovative drug licensing deals reached $106.3bn, according to VBInsight data published by VCBeat. That total covers inbound and outbound deals. That compares with $135.7bn for the whole of 2025 on the same provider’s count. This...

read more
Weekly News Roundup | 28 September 2026

Weekly News Roundup | 28 September 2026

Life science news 28 September 2026: four US drug approvals, three UK developments and two global R&D deals. The FDA approved Atebrioz, the third treatment for fibrodysplasia ossificans progressiva, and AbbVie’s Parkinson’s drug Juvmo. The MHRA approved...

read more
Multi-Cancer Early Detection Test Divides FDA Advisers

Multi-Cancer Early Detection Test Divides FDA Advisers

A United States advisory panel has recommended approval of a multi-cancer early detection blood test. The Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee met on 23 September 2026. It reviewed GRAIL’s Galleri test. The assay reads...

read more

Further News

Weekly News Roundup | 26 October 2026

Life science news 26 October 2026: two major deals, three US approvals, two UK updates and a reverse merger. Roche signed an antibody-drug conjugate deal with Hansoh. Merck KGaA agreed to buy Silence Therapeutics for about $1.3bn. The FDA granted accelerated approval...

Melanoma Vaccine Approval: When Could Intismeran Reach Patients?

Melanoma vaccine approval has not happened yet. No regulator has approved intismeran autogene, and its developers have not announced a filing date. On 22 October 2026, Merck and Moderna released detailed phase 3 data. They said they are engaging with regulatory...

Exosomes Move Toward the Mainstream. Manufacturing May Be the Key to Scale

For much of the past decade, exosomes have occupied a familiar place in biotechnology: scientifically intriguing, biologically versatile and full of potential, but still some distance from becoming routinely manufactured products. That is beginning to change as...

From Regulation to Adoption: What Europe Needs Next for AI in Health

The UK and EU have reached a pivotal point in the regulation of AI in health. Both have set ambitious goals for protecting patients while enabling innovation, but success will depend on whether regulatory frameworks can be translated into responsible adoption and...

Clinical Trial Results 23 October 2026

The clinical trial results 23 October 2026 cover non-infectious uveitis, hidradenitis suppurativa, IgA nephropathy, wet AMD and metastatic colorectal cancer. Priovant’s brepocitinib met its primary endpoint in two Phase 3 trials in non-infectious uveitis. AbbVie’s...

Fenebrutinib Approval: When Could the FDA Decide on Roche’s MS Drug?

Fenebrutinib approval is now under US priority review, but Roche has not said when the FDA will decide. The company announced on 30 September 2026 that the agency had accepted its new drug application. The filing covers relapsing multiple sclerosis (RMS) and primary...

Why US Federal Legislation Is the Best Chance to Rein In PBMs

Federal legislation is the best opportunity to compel pharmacy benefit managers (PBMs) to change. Neither a major Federal Trade Commission (FTC) settlement nor reforms at the state level have fixed market distortions. But the upcoming US midterm elections in November...

The Evidence Problem in Cosmetic Actives: Why In-Vitro Data Is Not Enough

As Head of R&D at a Swiss cosmetics laboratory, I read a lot of the evidence behind the cosmetic actives that brands ask us to put in their formulas. The same pattern keeps turning up. A well-cited in-vitro mechanism gets marketed as if it were a proven clinical...

Who Owns Ilofotase Alfa Now? Inside Ambrose’s AM-Pharma Deal

Ilofotase alfa now belongs to Ambrose Healthcare after a deal worth up to €161 million for AM-Pharma. The terms, the data and the HPP rivals.

    RNA-LNP Development: Creative Biolabs Links Design, Formulation & Analysis

    RNA delivery research is moving beyond conventional lipid nanoparticle (LNP) formulation toward a more systematic understanding of how lipid chemistry, particle organization, and intracellular trafficking influence delivery performance. As researchers confront...

    Bepirovirsen NHS Access: Will UK Hepatitis B Patients Get Hibsago?

    Bepirovirsen NHS access is undecided. Hibsago won FDA approval on 20 October 2026, but the UK has no authorisation. Here is what NICE and MHRA must do.

      Pediatric Eye Injuries: Severity, Referral and Permanent Vision Loss

      A child's vision is one of their most important developmental assets. Sight shapes how children learn, play, read, and connect with the world around them, and unlike many other aspects of health, vision loss caused by pediatric eye injuries can have consequences that...

      Want to Be Part of the Next Chapter in Life Sciences Media?

       

      LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

       

       

      Don’t wait for the media to pick up your story. Be the media.

      See More Articles

      Want to Be Part of the Next Chapter in Life Sciences Media?

       

      LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

       

       

      Don’t wait for the media to pick up your story. Be the media.